Literature DB >> 25301079

Clinical profile of uveitis-related ocular hypertension.

Deepankur Mahajan1, Reetika Sharma, Sat Pal Garg, Pradeep Venkatesh, Ramanjit Sihota, Tanuj Dada.   

Abstract

The purpose of this article is to study the clinical and demographic profile of uveitis-related ocular hypertension (OHT) and evaluate risk factors predisposing to development of OHT in uveitis. Two hundred patients (200 eyes) with uveitis were evaluated for type of uveitis and the presence of OHT [IOP > 21 mmHg]. All patients underwent a complete ophthalmic examination and appropriate systemic evaluation. Patients with OHT were started on appropriate antiglaucoma medication and were followed up for minimum of 6 months. Forty-two eyes (21 %) were found to have OHT. Anterior uveitis alone was seen in 22 (52.4 %), granulomatous uveitis was seen in 8 (19.1 %) eyes, while 13 eyes (30.9 %) had active uveitis. On multiple logistic regression, age greater than 60 years (p = 0.025), peripheral anterior synechiae (PAS) > 180° (p = 0.029), and steroid use (p < 0.001) were found to have significant association with OHT. Mean IOP at baseline was 24.6 ± 10.1 mmHg which decreased to 17.3 ± 4.5 mmHg at 6 months (p < 0.001). At 6 months, 30 eyes were medically controlled (71.4 %), 5 eyes underwent trabeculectomy with MMC (11.9 %), and in 7 eyes, antiglaucoma medication could be discontinued. One-fifth of eyes with uveitis had OHT. Risk factors for IOP elevation included increased age, PAS > 180°, and corticosteroid use.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301079     DOI: 10.1007/s10792-014-0008-8

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  16 in total

1.  International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.

Authors:  E Bloch-Michel; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

2.  Secondary Glaucoma.

Authors:  H C Agarwal; N N Sood; B R Kalra; B Ghosh
Journal:  Indian J Ophthalmol       Date:  1982-05       Impact factor: 1.848

Review 3.  Glaucoma associated with uveitis.

Authors:  R S Moorthy; A Mermoud; G Baerveldt; D S Minckler; P P Lee; N A Rao
Journal:  Surv Ophthalmol       Date:  1997 Mar-Apr       Impact factor: 6.048

4.  A clinical evaluation of uveitis-associated secondary glaucoma.

Authors:  Tetsuya Takahashi; Shinichiro Ohtani; Kazunori Miyata; Norio Miyata; Shiroaki Shirato; Manabu Mochizuki
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

5.  [Ocular hypertension and uveitis. Study of 374 cases of uveitis].

Authors:  N Saouli; A P Brézin
Journal:  J Fr Ophtalmol       Date:  1999-11       Impact factor: 0.818

6.  Secondary glaucoma in patients with uveitis.

Authors:  J Merayo-Lloves; W J Power; A Rodriguez; M Pedroza-Seres; C S Foster
Journal:  Ophthalmologica       Date:  1999       Impact factor: 3.250

7.  Ocular hypertension and secondary glaucoma in children with uveitis.

Authors:  Karen M Sijssens; Aniki Rothova; Tos T J M Berendschot; Joke H de Boer
Journal:  Ophthalmology       Date:  2006-05       Impact factor: 12.079

8.  Uveitis presenting de novo in the elderly.

Authors:  K Barton; C E Pavesio; H M Towler; S Lightman
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

Review 9.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

10.  Current profile of secondary glaucomas.

Authors:  Ritu Gadia; Ramanjit Sihota; Tanuj Dada; Viney Gupta
Journal:  Indian J Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 1.848

View more
  1 in total

1.  Characterization of Peripheral Anterior Synechiae Formation After Microhook Ab-interno Trabeculotomy Using a 360-Degree Gonio-Camera.

Authors:  Masato Matsuo; Yuina Inomata; Nana Kozuki; Masaki Tanito
Journal:  Clin Ophthalmol       Date:  2021-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.